Skip to Main Content

Paper Details

Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor.
Sci Transl Med
26
2021
AAA-ATPase, AML, ATM, CB-5339, MLL-AF9, MLL-AF9-, VCP, acute myeloid leukemia, adenosine, adenosine triphosphatase associated, anthracyclines, ataxia telangiectasia, ataxia telangiectasia mutated, cancer, cancer cells, dominant-negative VCP mutant, human, human AML cell lines, leukemic, mouse, murine, patient, primary patient samples, shRNA, short hairpin RNA, valosin, valosin-containing protein
Author NameAffiliation
Gabriela AlexeDana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School
Gabriela AlexeBroad Institute of Harvard University and Massachusetts Institute of Technology
Gabriela AlexeDana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School
Gabriela AlexeBroad Institute of Harvard University and Massachusetts Institute of Technology
Nina FenouilleUniversite de Paris, INSERM U944 and CNRS UMR 7212, Institut de Recherche Saint Louis
Edyta MalolepszaBroad Institute of Harvard University and Massachusetts Institute of Technology
Gaetano SodaroUniversite de Paris, INSERM U944 and CNRS UMR 7212, Institut de Recherche Saint Louis
Yana PikmanDana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School
Yana PikmanBroad Institute of Harvard University and Massachusetts Institute of Technology
Daniel J DeAngeloDana-Farber Cancer Institute, Harvard Medical School
Richard M StoneDana-Farber Cancer Institute, Harvard Medical School
Patrick AubergerINSERM U1065
Steven A CarrBroad Institute of Harvard University and Massachusetts Institute of Technology
Steven A CarrBroad Institute of Harvard University and Massachusetts Institute of Technology
Kasper LageBroad Institute of Harvard University and Massachusetts Institute of Technology
Alexandre PuissantUniversite de Paris, INSERM U944 and CNRS UMR 7212, Institut de Recherche Saint Louis, France. kimberly_stegmaier@dfci.harvard.edu alexandre.puissant@inserm.fr.
Kimberly StegmaierDana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, USA. kimberly_stegmaier@dfci.harvard.edu alexandre.puissant@inserm.fr.
Kimberly StegmaierBroad Institute of Harvard University and Massachusetts Institute of Technology
Kimberly StegmaierDana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, USA. kimberly_stegmaier@dfci.harvard.edu alexandre.puissant@inserm.fr.
Kimberly StegmaierBroad Institute of Harvard University and Massachusetts Institute of Technology
Lina BenajibaUniversite de Paris, INSERM U944 and CNRS UMR 7212, Institut de Recherche Saint Louis, France. kimberly_stegmaier@dfci.harvard.edu alexandre.puissant@inserm.fr.
  • 1 - 21

Datasets

Release 1.2